Abstract
A basic environmental risk assessment was carried out for the top 10 dispensed pharmaceuticals in Melbourne, Australia, in contrast to the more commonly assessed measure of the most used drugs by physical mass. This allowed for the evaluation of compounds that had not previously been the subject of risk assessment. Estimations of the possible fate and behaviour of the target pharmaceuticals in sewage treatment plants were also made. The predicted removal rates of most drugs within standard sewage treatment were expected to be low, with the exception of the statins, which had high removal rates. Each pharmaceutical was predicted to be present in Melbourne wastewater at the nanogram per litre range or lower. All compounds were predicted to be of low toxicity risk, although it was not possible to model mixture effects. Atorvastatin and Irbesartan were also found to possess the potential to possibly bioaccumulate in the aquatic food chain but not to the extent that would require regulation or labelling.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Rifai JH, Gabelish CL, Schäfer AI (2007) Occurrence of pharmaceutically active and non-steroidal estrogenic compounds in three different wastewater recycling schemes in Australia. Chemosphere 69(5):803–815. https://doi.org/10.1016/j.chemosphere.2007.04.069
Arnold WR, Cotsifas JS (2008) An assessment of the application factor used to derive the saltwater acute ambient water quality copper criterion. Integr Environ Assess Manag 4:252–254
AstraZeneca (2012) Nexium (esomeprazole magnesium) delayed-release capsules prescribing information. https://www.drugs.com/monograph/esomeprazole-magnesium.html. Accessed 22 Dec 2017
Australian Government Department of Health Australian Statistics on Medicine (2015) Benefits scheme and repatriation, section 85, http://www.pbs.gov.au/info/statistics/asm/asm-2015. Accessed 1/10/16
Australian Government Environment Protection Heritage Council, National Health and Medical Research Council, National Resource Management Ministerial Council (2008) Australian guidelines for water recycling: managing health and environmental risks (phase 2)—augmentation of drinking water supplies, Canberra
Beresford AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA (1988) Metabolism and kinetics of amlodipine in man. Xenobiotica 18(2):245–254. https://doi.org/10.3109/00498258809041660
Birch GF, Drage DS, Thompson K, Eaglesham G, Mueller JF (2015) Emerging contaminants (pharmaceuticals, personal care products, a food additive and pesticides) in waters of Sydney estuary, Australia. Mar Pollut Bull 97(1-2):56–66. https://doi.org/10.1016/j.marpolbul.2015.06.038
Castiglioni S, Fanelli R, Calamari D, Bagnati R, Zuccato E (2004) Methodological approaches for studying pharmaceuticals in the environment by comparing predicted and measured concentrations in River Po, Italy. Regul Toxicol Pharmacol 39(1):25–32. https://doi.org/10.1016/j.yrtph.2003.10.002
Crane M, Watts C, Boucard T (2006) Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ 367(1):23–41. https://doi.org/10.1016/j.scitotenv.2006.04.010
Daughton CG, Ternes TA (1999) Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect 107(Suppl 6):907–938. https://doi.org/10.1289/ehp.99107s6907
Derksen JGM, Rijs GBJ, Jongbloed RH (2004) Diffuse pollution of surface water by pharmaceutical products. Water Sci Technol 49:213–221
EPA Victoria and Melbourne Water (2009) Eastern treatment plant upgrade: information in support of a works approval application. http://www.epa.vic.gov.au/compliance-enforcement/comments/docs/ETP-Works-Approval-application-21July2009.pdf. Accessed 22/12/2017
EU (1994) Environmental risk assessment for human medicinal products containing or consisting of GMOs, III/5504/94 draft 4. European Commission, Brussels
Frishman WH, Cheng-Lai A, Chen J (2000a) Angiotensin-converting enzyme inhibitors. In: Frishman WH, Cheng-Lai A, Chen J (eds) Current cardiovascular drugs. Current Medicine Group, London, pp 18–44
Frishman WH, Cheng-Lai A, Chen J (2000b) Angiotensin-II receptor blockers. In: Frishman WH, Cheng-Lai A, Chen J (eds) Current cardiovascular drugs. Current Medicine Group, London, pp 45–53
Gomes RL, Meredith W, Snape CE, Sephton MA (2009) Analysis of conjugated steroid androgens: deconjugation, derivatisation and associated issues. J Pharm Biomed Anal 49(5):1133–1140. https://doi.org/10.1016/j.jpba.2009.01.027
Gomes RL, Scrimshaw MD, Cartmell E, Lester JN (2011) The fate of steroid estrogens: partitioning during wastewater treatment and onto river sediments. Environ Monit Assess 175(1-4):431–441. https://doi.org/10.1007/s10661-010-1541-1
Hafez HM, Elshanawane AA, Abdelaziz LM, Kamal MM (2013) Quantitative determination of three angiotensin-ii-receptor antagonists in presence of hydrochlorothiazide by RP-HPLC in their tablet preparations. Iranian J Pharm Res 12:635–643
Halling-Sørensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lützhøft HC, Jørgensen SE (1998) Occurrence, fate and effects of pharmaceutical substances in the environment—a review. Chemosphere 36(2):357–393. https://doi.org/10.1016/S0045-6535(97)00354-8
Hignite C, Azarnoff DL (1977) Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicylic acid in sewage water effluent. Life Sci 20(2):337–341. https://doi.org/10.1016/0024-3205(77)90329-0
Hughes SR, Kay P, Brown LE (2013) Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environ Sci Technol 47:661–677
Husain A, Azim M, Mitra M, Bhasin PS (2011) A review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharmacol Sci 1:12–17
Jobling S, Nolan M, Tyler CR, Brighty G, Sumpter JP (1998) Widespread sexual disruption in wild fish. Environ Sci Technol 32(17):2498–2506. https://doi.org/10.1021/es9710870
Johnson AC, Ternes T, Williams RJ, Sumpter JP (2008) Assessing the concentrations of polar organic microcontaminants from point sources in the aquatic environment: measure or model? Environ Sci Technol 42(15):5390–5399. https://doi.org/10.1021/es703091r
Jones OAH, Gomes R (2014) Chemical pollution of the aquatic environment by priority pollutants and its control. In: Harrison RM (ed) Pollution: causes, effects and control. RSC Publishing, London, pp 1–28
Jones OAH, Voulvoulis N, Lester JN (2002) Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 36(20):5013–5022. https://doi.org/10.1016/S0043-1354(02)00227-0
Jones OAH, Voulvoulis N, Lester JN (2003) Analytical method development for the simultaneous determination of five human pharmaceuticals in water and wastewater samples by gas chromatography-mass spectrometry. Chromatographia 58:471–477
Jones OA, Lester JN, Voulvoulis N (2005) Pharmaceuticals: a threat to drinking water? Trends Biotechnol 23(4):163–167. https://doi.org/10.1016/j.tibtech.2005.02.001
Jones OAH, Voulvoulis N, Lester J (2007a) The occurrence and removal of selected pharmaceutical compounds in a sewage treatment works utilising activated sludge treatment. Environ Pollut 145:738
Jones OAH, Voulvoulis N, Lester JN (2007b) Ecotoxicity of pharmaceuticals. In: Petrovic M, Barceló B (eds) Analysis, fate and removal of pharmaceuticals in the water cycle. Elsevier Scientific Publishing, Amsterdam, pp 387–424. https://doi.org/10.1016/S0166-526X(07)50012-7
Khan SJ, Ongerth JE (2002) Estimation of pharmaceutical residues in primary and secondary sewage sludge based on quantities of use and fugacity modelling. Water Sci Technol 46(3):105–113
Khan SJ, Ongerth JE (2004) Modelling of pharmaceutical residues in Australian sewage by quantities of use and fugacity calculations. Chemosphere 54(3):355–367. https://doi.org/10.1016/j.chemosphere.2003.07.001
Le Corre KS, Ort C, Kateley D, Allen B, Escher BI, Keller J (2012) Consumption-based approach for assessing the contribution of hospitals towards the load of pharmaceutical residues in municipal wastewater. Environ Int 45:99–111. https://doi.org/10.1016/j.envint.2012.03.008
Lyman WJ (1990) Adsorption coefficient for soils and sediments, Handbook of chemical property estimation methods: environmental behavior of organic compounds. American Chemical Society, Washington, DC
Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25(11):2822–2835. https://doi.org/10.1016/S0149-2918(03)80336-3
Melbourne Water (2016) Enhancing life and liveability—annual report 2015–2016. Melbourne Water, Melbourne. https://www.melbournewater.com.au/sites/default/files/Annual-Report-2016.pdf. Accessed 22 Dec 2017
Meylan WM, Howard PH, Boethling RS (1996) Improved method for estimating water solubility from octanol/water partition coefficient. Environ Toxicol Chem 15(2):100–106. https://doi.org/10.1002/etc.5620150205
Mompelat S, Le Bot B, Thomas O (2009) Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ Int 35(5):803–814. https://doi.org/10.1016/j.envint.2008.10.008
National Health and Medical Research Council (2011) Australian drinking water guidelines 6 (2011) version 3.1. Commonwealth of Australia, Canberra
Pfister M, Schaedeli F, Frey FJ, Uehlinger DE (1999) Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Br J Clin Pharmacol 47(6):645–651
Prescott LF (1980) Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 10(S2):291S–298S. https://doi.org/10.1111/j.1365-2125.1980.tb01812.x
Remko M (2009) Molecular structure and stability of perindopril erbumine and perindopril l-arginine complexes. Eur J Med Chem 44(1):101–108. https://doi.org/10.1016/j.ejmech.2008.03.012
Richardson ML, Bowron JM (1985) The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 37(1):1–12. https://doi.org/10.1111/j.2042-7158.1985.tb04922.x
Scott PD, Bartkow M, Blockwell SJ, Coleman HM, Khan SJ, Lim R, McDonald JA, Nice H, Nugegoda D, Pettigrove V, Tremblay LA, Warne MSJ, Leusch FDL (2014) A national survey of trace organic contaminants in Australian rivers. J Environ Qual 43(5):1702–1712. https://doi.org/10.2134/jeq2014.01.0012
Sonje VM, Kumar L, Meena CL, Kohli G, Puri V, Jain R, Bansal AK, Brittain HG (2010) Atorvastatin calcium. In: Brittain HG (ed) Profiles of drug substances, excipients, and related methodology. Academic Press, San Diego, pp 1–70
Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PAM, Marle SP, Tamminga WJ, Sollie FAE, Jonkman JHG (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J Clin Pharmacol 40:1312–1322
Stuer-Lauridsen F, Birkved M, Hansen LP, Holten Lützhøft HC, Halling-Sørensen B (2000) Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 40(7):783–793. https://doi.org/10.1016/S0045-6535(99)00453-1
Tauxe-Wuersch A, De Alencastro LF, Grandjean D, Tarradellas J (2005) Occurrence of several acidic drugs in sewage treatment plants in Switzerland and risk assessment. Water Res 39(9):1761–1772. https://doi.org/10.1016/j.watres.2005.03.003
Ternes TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. Water Res 32(11):3245–3260. https://doi.org/10.1016/S0043-1354(98)00099-2
The Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00 corr 2). European Medicines Agency, London
US EPA (2012) Estimation Programs Interface Suite™ for Microsoft® Windows. United States Environmental Protection Agency, Washington, DC
US Government Food and Drug Administration (1998) Guidance for industry: environmental assessment of human drug and biologics applications. Department of Health and Human Services, Rockville
US Government Food and Drug Administration (2015) Guidance for industry: determining the need for and content of environmental assessments for gene therapies, vectored vaccines, and related recombinant viral or microbial products. Department of Health and Human Services, Rockville
Verho M, Luck C, Stelter WJ, Rangoonwala B, Bender N (1995) Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin 13(5):264–273. https://doi.org/10.1185/03007999509111551
Waggot A (1981) Trace organic substances in the River Lee (Great Britain). In: Cooper WJ (ed) Trace organic substances in the River Lee (Great Britain), in Chemistry in water reuse. Ann Arbour Science, Ann Arbor, pp 55–99
Weber S, Khan S, Hollender J (2006) Human risk assessment of organic contaminants in reclaimed wastewater used for irrigation. Desalination 187:53–64
Wu Q, Shi H, Adams CD, Timmons T, Ma Y (2012) Oxidative removal of selected endocrine-disruptors and pharmaceuticals in drinking water treatment systems, and identification of degradation products of triclosan. Sci Total Environ 439:18–25. https://doi.org/10.1016/j.scitotenv.2012.08.090
Ying G-G, Kookana RS (2007) Triclosan in wastewaters and biosolids from Australian wastewater treatment plants. Environ Int 33(2):199–205. https://doi.org/10.1016/j.envint.2006.09.008
Ying GG, Kookana RS, Dillon P (2003) Sorption and degradation of selected five endocrine disrupting chemicals in aquifer material. Water Res 37(15):3785–3791. https://doi.org/10.1016/S0043-1354(03)00261-6
Zwiener C (2007) Occurrence and analysis of pharmaceuticals and their transformation products in drinking water treatment. Anal Bioanal Chem 387(4):1159–1162. https://doi.org/10.1007/s00216-006-0818-2
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible editor: Ester Heath
Rights and permissions
About this article
Cite this article
Ong, T.T.X., Blanch, E.W. & Jones, O.A.H. Predicted environmental concentration and fate of the top 10 most dispensed Australian prescription pharmaceuticals. Environ Sci Pollut Res 25, 10966–10976 (2018). https://doi.org/10.1007/s11356-018-1343-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11356-018-1343-5